AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.

PRAVASTATIN (Oral route) - PRA-va-stat-in.(Drug overview)

USP DI-Volume II, Advice for the Patient: Drug Information in Lay Language

| May 01, 2007 | COPYRIGHT 1996 USP DIĀ® and Advice for the PatientĀ® are registered trademarks of USP used under license to Micromedex, Inc. (Hide copyright information)Copyright

Brand names in the United States --

* Pravachol

Dosage forms --

* Tablet

Therapeutic classification: Antihyperlipidemic

Pharmacologic classification: HMG-COA Reductase Inhibitor

DESCRIPTION OF USE

Pravastatin is used together with proper diet to treat high cholesterol levels in the blood. Using this medicine may help prevent medical problems caused by such substances clogging the blood vessels. This medicine may also be used to prevent certain types of heart problems in patients with risk factors for heart problems .

Pravastatin belongs to the group of medicines called 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. It works by blocking an enzyme that is needed by the body to make cholesterol, thereby reducing the amount of cholesterol in the blood .

Pravastatin is available only with your doctor's prescription .

Before prescribing medicine for your condition, your doctor will probably try to control your condition by prescribing a personal diet for you. Such a diet may be low in fats, sugars, and/or cholesterol. Many people are able to control their condition by carefully following their doctor's orders for proper diet and exercise. Medicine is prescribed only when additional help is needed and is effective only when a schedule of diet and exercise is properly followed .

BEFORE USING THIS MEDICINE

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following …

Related articles from newspapers, magazines, journals, and more
Landmark three-year clinical trial confirms for the first time the benefit of...
News wire article from: Asia Africa Intelligence Wire November 18, 2002 700+ words
European Medicines Agency decision of 15 Jun 2009 on the granting of a...
News wire article from: Chemical Business Newsbase August 11, 2009 700+ words
Public summary of opinion on orphan designation: Pravastatin/zoledronic acid...
News wire article from: Chemical Business Newsbase June 23, 2010 700+ words
Summary of opinion (initial authorisation): Pravafenix...
News wire article from: Chemical Business Newsbase January 21, 2011 700+ words
Ranbaxy clarifies 180-day exclusivities relating to Pravastatin 80 mg and...
News wire article from: Asia Africa Intelligence Wire October 31, 2005 700+ words
©2013 Gale, a part of Cengage Learning. All rights reserved. Contact us | Privacy policy | Terms and conditions

The AccessMyLibrary advertising network includes: womensforum.com GlamFamily